国产中文无码av每日更新在线观看, 亚洲天堂中文字幕一区二区三区免费, 国产口爆吞精在线观视频-黄色国产, 92福利-国内精品久久久久久99,亚洲成AV人A片不卡无码,浪潮AV无码专区,老熟女败火白浆,中文字幕日产av,色情日本免费看大片

更新于 11月21日

車間操作工(J10329)

4000-5000元
  • 滄州黃驊市
  • 1-3年
  • 大專
  • 全職
  • 招1人

職位描述

合成工藝
崗位職責(zé):
1、按生產(chǎn)指令單和車間的統(tǒng)一安排,及時(shí)領(lǐng)回生產(chǎn)用原輔料、包裝材料等,并認(rèn)真核對(duì)品名、數(shù)量、規(guī)格、批號(hào)等內(nèi)容;
2、嚴(yán)格按照相關(guān)操作規(guī)程生產(chǎn)化學(xué)原料藥,保證嚴(yán)格執(zhí)行生產(chǎn)工藝規(guī)程和崗位操作規(guī)程,嚴(yán)格執(zhí)行安全生產(chǎn)操作規(guī)程,確保產(chǎn)品質(zhì)量,確保安全生產(chǎn);
3、按要求佩戴勞保用品;
4、按規(guī)定操作設(shè)備,按要求維護(hù)保養(yǎng)設(shè)備;
5、認(rèn)真、及時(shí)、真實(shí)填寫生產(chǎn)操作記錄以及輔助記錄;
6、按照清潔操作規(guī)程,及時(shí)做好生產(chǎn)清潔衛(wèi)生工作。
任職要求:
1、化工相關(guān)專業(yè),大專及其以上學(xué)歷,接受倒班,應(yīng)屆畢業(yè)生、實(shí)習(xí)生均可;
2、具備積極進(jìn)取的工作態(tài)度和良好的學(xué)習(xí)能力,能夠快速適應(yīng)新環(huán)境。

工作地點(diǎn)

滄州黃驊市黃驊東/中捷/臨港開(kāi)發(fā)區(qū)出口

職位發(fā)布者

錢晶晶/招聘經(jīng)理

剛剛活躍
立即溝通
公司Logo北京康蒂尼藥業(yè)股份有限公司
北京康蒂尼藥業(yè)股份有限公司創(chuàng)立于2002年,是一家以器官纖維化疾病為核心,集研發(fā)、生產(chǎn)、銷售于一體的創(chuàng)新藥物開(kāi)發(fā)企業(yè)。北京康蒂尼為美國(guó)納斯達(dá)克上市公司Gyre Therapeutics, Inc.(股票簡(jiǎn)稱:GYRE)的控股子公司。作為器官纖維化領(lǐng)域的先行者,公司的旗艦產(chǎn)品1.1類新藥艾思瑞?(吡非尼酮膠囊)是全球唯二已獲批且受指南推薦的特發(fā)性肺纖維化(IPF)治療藥物,也是國(guó)內(nèi)首款用于治療IPF的創(chuàng)新藥物,2014年成功上市后填補(bǔ)了該領(lǐng)域的空白。公司下一階段關(guān)鍵性產(chǎn)品—治療肝纖維化的F351(羥尼酮)被藥審中心認(rèn)定為“突破性治療藥物”,有望成為全球首款獲批治療慢性乙肝(CHB)相關(guān)纖維化的藥物。公司將通過(guò)艾思瑞?積累的從自主開(kāi)發(fā)到商業(yè)化成功的完整經(jīng)驗(yàn)豐富并推進(jìn)產(chǎn)品管線,將治療領(lǐng)域逐漸拓寬至其他器官纖維化,研究和開(kāi)發(fā)治療肺纖維化、肝纖維化及腎纖維化的創(chuàng)新藥品,為更多器官纖維化患者帶來(lái)新希望。Beijing Continent Co., Ltd was founded in 2002, which is a innovate drug development enterprise committed to organ fibrosis diseases, and integrated R&D, production and commercialization. Beijing Continent is the holding subsidiary of the NASDAQ-listed company Gyre Therapeutics, Inc.(Stock Ticker: GYRE).s a pioneer in the field of anti-organ fibrosis, company’s flagship product Class 1.1 new drug ETUARY?(Pirfenidone Capsule) is one of the only two types approved drugs for IPF treatment worldwide. As the first innovate drug approved to be used for IPF in China, it filled the gap in the IPF treatment field after its successful launch in 2014. F351(Hydronidone) the company’s key production for next stage, was granted a Breakthrough Therapy designation as the liver fibrosis treatment drug by the CDE. It is expected to be the first approved drug for the treatment of liver fibrosis associated with CHB.The company will enrich and boost the product pipeline by utilizing our successful and complete experience accumulated from in-house development to commercialization of ETUARY?. We are expanding our therapeutic field to other organs fibrosis by researching and developing the treatment of pulmonary fibrosis, liver fibrosis and renal fibrosis to bring new hope to the patients with organs fibrosis.
公司主頁(yè)